Identification and Functional Validation of the Novel Antimalarial Resistance Locus PF10_0355 in Plasmodium falciparum

|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Identification and Functional Validation of the Novel Antimalarial Resistance Locus \textit{PF10\_0355} in \textit{Plasmodium falciparum}

Daria Van Tyne$^1$, Daniel J. Park$^{2,3}$, Stephen F. Schaffner$^2$, Daniel E. Neafsey$^2$, Elaine Angelino$^{4,5}$, Joseph F. Cortese$^2$, Kayla G. Barnes$^1$, David M. Rosen$^1$, Amanda K. Lukens$^1$, Rachel F. Daniels$^{2,6}$, Danny A. Milner, Jr$^1$, Charles A. Johnson$^2$, Ilya Shlyakhter$^{2,3,4}$, Sharon R. Grossman$^{2,3,4,5}$, Justin S. Becker$^1$, Daniel Yamins$^2$, Elinor K. Karlsson$^{2,3,4}$, Daouda Ndiaye$^7$, Ousmane Sarr$^7$, Souleymane Mboup$^7$, Christian Happi$^8$, Nicholas A. Furlotte$^9$, Eleazar Eskin$^9$, Hyun Min Kang$^{10}$, Daniel L. Hart$^3$, Bruce W. Birren$^2$, Roger C. Wiegand$^2$, Eric S. Lander$^2$, Dyann F. Wirth$^{1,2}$, Sarah K. Volkman$^{1,2,11}$, Pardis C. Sabeti$^{2,3,4}$

1 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA
2 Broad Institute, Cambridge, Massachusetts, USA
3 Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA
4 FAS Center for Systems Biology, Harvard University, Cambridge, Massachusetts, USA
5 Harvard Medical School, Boston, Massachusetts, USA
6 Biological and Biomedical Sciences, Harvard University, Cambridge, Massachusetts, USA
7 Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal
8 Malaria Research Laboratories, College of Medicine, University of Ibadan, Ibadan, Nigeria
9 Department of Computer Science & Department of Human Genetics, University of California, Los Angeles, California, USA
10 Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA
11 School for Health Sciences, Simmons College, Boston, Massachusetts, USA

* These authors contributed equally
Abstract

The *Plasmodium falciparum* parasite’s ability to adapt to environmental pressures, such as the human immune system and antimalarial drugs, makes malaria an enduring burden to public health. Understanding the genetic basis of these adaptations is critical to intervening successfully against malaria. To that end, we created a high-density genotyping array that assays over 17,000 single nucleotide polymorphisms (~1 SNP/kb), and applied it to 57 culture-adapted parasites from three continents. We characterized genome-wide genetic diversity within and between populations and identified numerous loci with signals of natural selection, suggesting their role in recent adaptation. In addition, we performed a genome-wide association study (GWAS), searching for loci correlated with resistance to thirteen antimalarials; we detected both known and novel resistance loci, including a new halofantrine resistance locus, *PF10_0355*. Through functional testing we demonstrated that *PF10_0355* overexpression decreases sensitivity to halofantrine, mefloquine and lumefantrine but not to structurally unrelated antimalarials, and that increased gene copy number mediates resistance. Our GWAS and follow-on functional validation demonstrate the potential of genome-wide studies to elucidate functionally important loci in the malaria parasite genome.
Author Summary

Malaria infection with the human pathogen, *Plasmodium falciparum*, results in almost a million deaths each year, mostly in African children. Efforts to eliminate malaria are underway, but the parasite is adept at eluding both the human immune response and antimalarial treatments. Thus, it is important to understand how the parasite becomes resistant to drugs and to develop strategies to overcome resistance mechanisms. Toward this end, we used population genetic strategies to identify genetic loci that contribute to parasite adaptation and to identify candidate genes involved in drug resistance. We examined over 17,000 genetic variants across the parasite genome in over 50 strains in which we also measured responses to many known antimalarial compounds. We found a number of genetic loci showing signs of recent natural selection and a number of loci potentially involved in modulating the parasite’s response to drugs. We further demonstrated that one of the novel candidate genes (*PF10_0355*) modulates resistance to the antimalarial compounds halofantrine, mefloquine and lumefantrine. Overall, this study confirms that we can use genome-wide approaches to identify clinically relevant genes and demonstrates through functional testing that at least one of these candidate genes is indeed involved in antimalarial drug resistance.
Introduction

*Plasmodium falciparum* malaria is a major public health challenge that contributes significantly to global morbidity and mortality. Efforts to control and eliminate malaria combine antimalarial drugs, bed nets and indoor residual spraying, with vaccine development a longer-term goal. Genetic variation in the parasite population threatens to undermine these efforts, as the parasite evolves rapidly to evade host immune systems, drugs and vaccines. Studying genetic variation in parasite populations will expand our understanding of basic parasite biology and its ability to adapt, and will allow us to track parasites as they respond to intervention efforts. Such understanding is increasingly important as countries move towards reducing disease burden and the ultimate elimination of malaria.

Given the potential impact of rapid evolution of *P. falciparum* in response to control and eradication strategies, discovery and characterization of *P. falciparum* genetic diversity has accelerated in recent years. Since the first malaria genome was sequenced in 2002 [1], over 60,000 unique SNPs have been identified by concerted sequencing efforts [2-4], and several genomic tiling arrays [5-9] and low-density SNP arrays [10,11] have been developed to query this genetic variation. Recently the first malaria GWAS was published [11], in which 189 drug-phenotyped parasites from Asia, Africa and the Americas were genotyped using a low-density array (3,257 SNPs); that study identified loci under positive selection and found several novel drug resistance candidates.
For our study, we adopted two strategies for identifying genes involved in the malaria parasite’s adaptive response: searching for signals of recent or ongoing natural selection, and searching for loci associated with one important clinical adaptation—resistance to antimalarial drugs. To make these searches possible, we began by sequencing 9 geographically diverse strains of *P. falciparum* to identify novel variation, thereby doubling the number of publicly available SNPs to 111,536 (all accessible at plasmodb.org), and used these SNPs to develop a high-density genotyping array assaying 17,582 validated markers. After characterizing linkage disequilibrium and population structure in our samples, we used the arrays to search for evidence of both ongoing balancing selection and recent positive selection, and to carry out a GWAS that sought loci associated with resistance to thirteen antimalarial agents. We then followed up one of the novel loci associated with drug resistance in order to verify that variation there was biologically involved in modulating drug response.

**Results**

**Genetic Diversity**

We identified global population structure among malaria parasites using principal components analysis (PCA) of 57 genotyped culture-adapted parasite samples (Figure 1A, Table S1, Figure S1). African, American and Asian samples form three distinct clusters, reflecting the likely independent introduction of *P. falciparum* from Africa into Asia and the Americas. There was little evidence for structure within Africa, suggesting high gene flow throughout the region (Figure S1). Asian and American parasites however both show substantial internal structure.
There are also dramatic differences in linkage disequilibrium (LD) between populations, with substantial LD extending less than 1 kb in Senegal, 10 kb in Thailand, and 100 kb in Brazil (Figure S2). These observations are consistent with previous findings, which showed that LD decays more rapidly in Africa, due either to founder effects in other continents [12] or to elevated outcrossing frequencies in Africa [12,13], where higher transmission intensity leads to a greater likelihood of sexual outcrossing rather than selfing within the mid-gut of vector mosquitoes.

The short LD in malaria, driven by high levels of recombination, means that a high density of markers is required to identify candidate loci in association studies, since causal variants not on the array can seldom be tagged by neighboring alleles (Table S2). On the other hand, short LD can aid in fine-mapping candidate associations and greatly accelerates the search for causal genes. Short LD also aids in identifying genomic regions under recent positive selection with recombination-based methods, since the increased LD in selected regions should stand out against the short-LD background.

Detecting Signals of Natural Selection

We expect that many parasite proteins that interact with the host immune system will be under balancing selection, because they will be under selective pressure to maintain high levels of diversity. Indeed, previous studies have shown that regions of the *P. falciparum* genome that are highly polymorphic and appear to be under balancing selection encode antigens that are recognized by the human immune system [4]. We examined evidence for balancing selection in our data by searching for regions with high nucleotide diversity (as measured by SNP π) and low population divergence (as measured by *F*<sub>ST</sub>) (Figure
When we examined the loci lying in this region of the graph (Figure S3), we found a number of known antigens and vaccine candidates. Loci in the same region with unknown function are thus potential novel antigens that trigger human immune response to malaria, and may prove useful as biomarkers or as candidate vaccine molecules.

We carried out a similar search for loci under positive selection by identifying regions with both low nucleotide diversity within Senegal and Thailand and high population divergence between the two populations (Figure 1B). We observed throughout the genome that nucleotide diversity was lower for nonsynonymous SNPs than for intergenic SNPs (Figure S4), a characteristic result of widespread purifying selection. At the same time, nonsynonymous SNPs exhibited significantly greater divergence than intergenic SNPs in all pairwise population comparisons, suggesting the effect of positive selection in local *P. falciparum* populations. Nonsynonymous SNPs with low diversity within a population and high divergence between the two populations studied may represent polymorphisms responsible for adaptive evolution.

We also carried out a genome-wide scan for recent positive selection using the long-range haplotype (LRH) test [14], which identifies common variants that have recently spread to high prevalence using recombination as a clock. Approximately 15 genes were identified as having undergone recent positive selection by this approach, including known drug resistance loci (*pfcr* and *dhfr*) as well as multiple members of the acyl-CoA synthetase (ACS) and ubiquitin protein ligase families (Figure S5 and S6); these latter genes also exhibit high divergence between Senegal and Thailand (Figure 1B), evidence for selection that is recent and population-specific. Taken as a group, the genes identified
by the LRH test show a significant enrichment for higher than average population
divergence (as measured by $F_{ST}$, Mann-Whitney $U=1583$, $P=0.0071$). All of these loci
(Table S3, Dataset S1), which include genes in the folate metabolism, lipid biosynthesis
and ubiquitin pathways, should be viewed as candidates for functional follow-up and
further characterization.

Genome-wide Associations with Drug Resistance

In order to directly assess the genetic basis for one important response to antimalarial
intervention, we carried out a GWAS to identify loci associated with drug resistance in
parasites. This same approach can potentially be applied to many other clinically
relevant malaria phenotypes, e.g. host response, invasion, and gametocyte formation. Our
first step was to measure drug resistance ($IC_{50}$ values) to 13 antimalarial drugs
(amodiaquine, artemether, artesunate, artemisinin, atovaquone, chloroquine,
dihydroartemisinin, halofuginone, halofantrine, lumefantrine, mefloquine, piperaquine
and quinine) in 50 culture-adapted parasites using a high-throughput assay (Tables S4
and S5, Text S1, Dataset S1).

We performed the genome-wide association analysis using two statistical tests: efficient
mixed-model association (EMMA) and a haplotype likelihood ratio (HLR) test (Figures
S7-S10, Methods). EMMA identifies quantitative trait associations in individuals with
complex population structure and hidden relatedness; it has previously been shown to
outperform both PCA-based and $\lambda_{GC}$-based correction approaches in highly inbred and
structured mouse, maize, and Arabidopsis populations [15]. EMMA is particularly
applicable for small and structured sample sets: one of its first applications was in a study
of 24 diploid mouse strains [15], essentially the same sample size as in our study (50 haploid strains). The HLR test is a multi-marker test designed to detect the association of a single haplotype with a phenotype, and is particularly powerful when the associated haplotype experienced recent strong selection (and is therefore long) and occurs on a low-LD background [16]; it is therefore particularly appropriate for this study. We addressed the effect of population structure in the HLR test using population-specific permutation (Methods). When used together, these two complementary approaches provide a highly sensitive screen for association signals within the *P. falciparum* genome.

The well-characterized chloroquine resistance locus, *pfcr*, served as a positive control for our GWAS methods (Figure 2A and 2C, Table S2), an important test given our small sample size and the limited LD present in *P. falciparum*. As expected, we found evidence for association with resistance to chloroquine using both tests, consistent with previous studies [11]; EMMA yielded evidence for association with genome-wide significance, while the signal from the HLR test fell just short of genome-wide significance (Figure 2C).

Applying the same tests to the other drug phenotypes, we detected numerous novel loci showing significant associations with drug resistance (Figure 2A and 2D, Table 1). Quantile-quantile plots for each test demonstrate that we were able to effectively control for population structure (Figure 2B). Despite our small sample size and the low LD in *P. falciparum*, in total eleven loci achieved genome-wide significance for association with resistance to five different drugs: amodiaquine, artemisinin, atovaquone, chloroquine and halofantrine. In most cases, the short extent of LD allowed localization to individual
genes. Among the loci identified were various transporters and membrane proteins, as well as five conserved genes with unknown function (Table 1, Dataset S1).

Functional Validation of a Novel Resistance Candidate

Demonstrating that a signal of association actually reflects a causal molecular process requires functional testing and validation of the candidate locus, both because of concerns about power and reproducibility of genetic association tests, and because even a robust statistical correlation need not imply biological causation. To confirm the ability of GWAS to identify functionally relevant candidates, we investigated one of our association findings, *PF10_0355*, in greater depth. This gene contains multiple SNPs associated with halofantrine resistance (Figure 2D), and encodes a putative erythrocyte membrane protein (PlasmoDB.org) characterized by high genetic diversity.

We set out to determine the role of *PF10_0355* in halofantrine resistance by transfecting halofantrine-sensitive Dd2 parasites with episomal plasmids containing the *PF10_0355* gene from a halofantrine-resistant parasite (SenP08.04), a technique that is used routinely for stable transgene expression [17]. Two independent transfectants overexpressing the *PF10_0355* gene from SenP08.04 both showed reduced susceptibility to halofantrine when compared with the Dd2 parent or a transfection control (Figure 3A), suggesting that this gene is indeed involved in modulating parasite drug response.

Two independent transfectants overexpressing the endogenous *PF10_0355* gene from halofantrine-sensitive Dd2 also showed reduced susceptibility to halofantrine (Figure 3A), however, pointing to a role of overexpression in the observed resistance. Because
*PF10_0355* is annotated as a putative erythrocyte membrane protein and belongs to the merozoite surface protein 3/6 family, we tested the hypothesis that the observed effect was the by-product of a growth or invasion-related process, rather than resistance due to a direct interaction with the antimalarial itself. To that end, we expanded our drug testing in the transfectant lines to include other antimalarials, some structurally related and some unrelated to halofantrine.

Overexpression of *PF10_0355* from either the Dd2 or the SenP08.04 parent caused increased resistance to the structurally related antimalarials mefloquine and lumefantrine (Figure 3B and 3C), but had no effect on parasite susceptibility to the structurally unrelated antimalarials chloroquine, artemisinin or atovaquone (Figure 3D and 3E). Indeed, we found evidence of cross-resistance between halofantrine and both mefloquine and lumefantrine (Figure 4). We also observed cross-resistance between halofantrine and artemisinin, which is expected as cross-resistance between aminoquinolines and artemisinin compounds has been previously demonstrated [11,18] and resistance to all these drugs has been shown to be mediated by changes in *pfmdr1* copy number [19,20]. Overexpression of *PF10_0355*, however, alters parasite susceptibility to the aminoquinolines but not to artemisinin, suggesting that this effect is specific for that set of structurally related compounds and distinct from the effect of *pfmdr1*, which seems to exert a global effect of resistance to unrelated compounds (i.e. both aminoquinolines and artemisinins). Using the Dd2 parasite line, which has amplified *pfmdr1* copy number, as a background for *PF10_0355* overexpression allowed us to distinguish between cross-resistance to a structurally related class of compounds (mediated by *PF10_0355* overexpression) and pan-resistance to multiple classes of drugs.
Given that overexpression of the \textit{PF10\_0355} gene both from a halofantrine-resistant and from a sensitive parasite conferred resistance to halofantrine-related drugs, we investigated whether gene amplification might be driving the observed resistance, as it often does for antimalarial drugs [21-26]. We quantified \textit{PF10\_0355} copy number in our transfectants and found that the transfectant with the highest IC$_{50}$ for all three drugs (Dd2+P08B) also had the highest \textit{PF10\_0355} copy number, as measured by quantitative PCR (qPCR) (Figure 5A). Furthermore, when we examined the \textit{PF10\_0355} gene on our SNP array, we detected a substantial increase in hybridization intensity at the \textit{PF10\_0355} locus compared to the genome average, suggesting that this gene is amplified in some parasites (Figure 5B). The amplified region appears only to contain the \textit{PF10\_0355} gene itself and not surrounding loci. We observed a similar pattern at \textit{pfmdr1} on chromosome 5, where copy number variation is well established (Figure S11). Follow-up qPCR analysis of 38 parasite lines confirmed that parasites with amplified \textit{PF10\_0355} have a greater mean halofantrine IC$_{50}$. (Figure 5C, Table S6, Dataset S1). Copy number variation was further confirmed in a number of parasites by quantitative Southern blotting (Figure S12).

**Discussion**

In this study we used natural selection and genome-wide association methods to probe the genetic basis of adaptation in \textit{P. falciparum}. These approaches are complementary: scanning for selected loci permits an unbiased search for unknown adaptive changes, but provides little information about the processes at work, while GWAS gives a focused look at one easily identified (and clinically critical) adaptive phenotype. Results from
both approaches open up new avenues for study, as we seek to understand the biological significance of the findings.

The specifics of our strategy were designed to cope with two potential limitations in applying genome-wide population genetic approaches to malaria: small sample sizes, due to the difficulty in adapting parasites to culture and assessing drug and other phenotypes; and a lack of correlation (LD) between nearby variants in the parasite genome, which limits our ability to infer untyped SNPs from genotyped markers. The second limitation we addressed by developing a high-density genotyping array (based on new sequencing), to increase the fraction of genetic variation that we could directly interrogate, while the effect of the first was mitigated by the phenotype we targeted in our GWAS.

Drug resistance is a phenotype well-suited for GWAS because it is expected to be caused by common alleles of large effect at few genomic loci [27]. If this is the case, associations will be much easier to detect than in a typical human GWAS, in which the phenotype is caused by alleles at many loci that are either rare or of small effect. Additionally, the haploid nature of the intra-erythrocytic stage of *P. falciparum* further heightens GWAS power by eliminating the issue of allelic dominance. Finally, the increased LD caused by recent selection for drug resistance counteracts the loss of power that comes from short LD, small sample size, and the temporal and geographic stratification of the parasite population that we examined. Thus, despite the potential limitations, we were able to detect a known drug resistance locus (*pfcrt*), observed little *P*-value inflation in our GWAS data (Figures S8-S10), and identified a number of
genome-wide significant loci associated with drug resistance. Part of this success was likely due to specific tests we used to account for population structure.

Going beyond these statistical tests, we went on to functionally validate one of these loci, demonstrating that increased \textit{PF10\_0355} copy number confer resistance to three structurally related antimalarial drugs. This demonstrates the feasibility of coupling GWAS and functional testing in the malaria parasite for identifying and validating novel drug resistance loci and illustrates the power of GWAS to find functionally important alleles.

Comparing our results to the recent GWAS described by Mu, et al. [11], which was also directed at finding drug-resistance loci, we see that, beyond the well-known \textit{pfcrt} locus, there was no overlap between the associations identified by each study. Differing sets of drugs tested and analytical methods explain much of the disagreement. Of the eleven candidate associations in Table 1, one (that with \textit{pfcrt}) was found by both studies, eight were associations with drugs not assayed in Mu, et al. (atovaquone and halofantrine), and two were found only with a haplotype-based test, an approach not used by Mu, et al. Our candidate locus at \textit{PF10\_0355}, in fact, would not have been detectable in the Mu study because it was identified only by the multi-marker HLR test, because it involved an association with halofantrine, and because the Mu, et al. genotyping array lacked markers within 4 kb of the gene (plasmoDB.org).

Different parasite populations and marker sets probably explain many of the dihydroartemisinin, mefloquine and quinine associations identified by Mu, et al. but not
seen in our data set. The studies used different parasite population sets—theirs was weighted toward southeast Asian strains, and ours toward African strains—and selection pressures and selected alleles can both vary between populations. Our smaller sample size also means that we might lack power to identify some associations accessible to Mu, et al. These difficulties are reflected in human GWAS studies as well, where the ability to replicate associations using multiple tests and in different sample sets has also been challenging to achieve [28].

Ultimately, the disparities in loci identified point to the role of population analysis as a tool for candidate gene discovery and not as a definitive study. Even within each study, there is little overlap between the signals observed with different methods—our study detects only one gene (pfcrt) by both GWAS tests (EMMA and HLR), while Mu, et al. detected only two genes (unknowns, not pfcrt) by both of their GWAS tests (Eigensoft and PLINK). Even a well-designed GWAS serves only as a hypothesis-generating experiment, and it is vital to empirically validate candidate loci associated with a phenotype of interest. Especially given the small sample sizes and relatively sparse marker density used in both malaria GWAS studies to date, functional validation of candidates is necessary to address concerns about false positive results.

Our functional result, that increased PF10_0355 copy number confers decreased susceptibility to halofantrine, mefloquine and lumefantrine, raises additional questions for study. Further work will be needed to determine the precise contributions of copy number variation and gene mutation to the parasite’s response to these drugs. The biological function of this gene’s product is unknown, but previous work indicates
putative localization to the parasite surface [29], as well as it being a potential target of host immunity and balancing selection [30]. While the protein itself does not appear to be a transporter, it is possible that it directly binds drug or perhaps couples with transport proteins to modulate drug susceptibility; interaction between membrane transporters and non-channel proteins has been demonstrated in cancer, plant and yeast systems [31-33]. Additional experiments are certainly required to determine the precise role of PF10_0355 in modulating parasite response to this class of compounds, including assessing its relevance to resistance in natural populations, but it is clear that alteration of this locus can mediate drug resistance in P. falciparum.

Although halofantrine, mefloquine and lumefantrine are not commonly used as primary interventions, widespread halofantrine use has recently been documented in West Africa. Notably, halofantrine was used to treat nearly 18 million patients between 1988 and 2005 [34,35], and it remains in production and use today. Use of halofantrine, mefloquine or lumefantrine as monotherapy may further explain how mutations and copy number variation in the PF10_0355 gene were selected. Lumefantrine is also currently used as a partner drug in the artemisinin-based combination therapy (ACT) Coartem. The shorter half-life of artemether allows lumefantrine to be present as monotherapy, making it vulnerable to selection of drug resistant mutants. As genetic loci associated with drug responses are identified and validated, these provide new molecular biomarkers to evaluate drug use and response in malaria endemic settings. Thus, our findings have implications for defining molecular biomarkers for monitoring partner drug responses as intervention strategies, such as ACTs, are applied.
Beyond identifying a novel drug resistance locus, this study illustrates the general utility of a GWAS approach for the discovery of gene function in *P. falciparum*. Even with a small and geographically heterogeneous sample of parasites, we identified a number of new loci associated with drug response and validated one of them. Larger samples from a single population will have much greater power to detect additional loci, including those where multiple and low frequency alleles contribute to resistance. Future GWAS have the potential both to provide greater insights into basic parasite biology and to identify biomarkers for drug resistance and other clinically relevant phenotypes like acquired protection, pathogenesis, and placental malaria.

Future GWAS will be able to counteract the loss of power caused by low LD, either by focusing on parasite populations with reduced outcrossing rates, or by studying cases of very strong selective pressure. This issue will soon become moot, however, as the declining cost of whole-genome sequencing makes it practical to assay every nucleotide in the genome on a routine basis. Culture-adapted parasites are amenable to robust and reproducible phenotypic characterization, but their limitations—the potential for artifactual mutations during adaptation and for a biased selection of clones within a given infection—mean that genetic changes identified using them require both functional validation and demonstration that the changes are important during natural infection. As direct sequencing of clinical isolates with demonstrable clinical phenotypes such as *ex vivo* drug response or invasion properties becomes increasingly feasible, sequencing will enable us to directly identify genetic changes in the parasite associated with clinically relevant phenotypes. In the years ahead, genome analysis of *P. falciparum* has the
potential to identify genetic loci associated with many phenotypes, enhance our understanding of the biology of this important human pathogen, and inform the development of diagnostic and surveillance tools for malaria eradication.
Methods

Parasites, Drug Testing, and DNA Isolation

Parasite samples and origins are detailed in Text S1 and Table S1. Parasites were maintained by standard methods [36] and were tested for their response to amodiaquine, artemether, artesunate, artemisinin, atovaquone, chloroquine, dihydroartemisinin, halofuginone, halofantrine, lumefantrine, mefloquine, piperaquine and quinine according to the methods outlined by Baniecki, et al. [37] (Table S4, Figure S13, Text S1). Follow-up drug testing was done by measuring uptake of $^3$H-hypoxanthine [38]. Nucleic acids were obtained from parasite cultures using Qia gen genomic-tips (Qiagen, USA). All DNA samples were evaluated by molecular barcode [39].

Array Genotyping

We sequenced nine geographically diverse parasite isolates to 1.25x coverage, nearly doubling the number of publicly available SNPs to 111,536 (Text S1). These parasites had been previously sequenced to 0.25x coverage [2] and the deeper sequencing allowed for more thorough SNP discovery. Using this combined marker set, we created a high-density Affymetrix-based SNP array for *P. falciparum* containing 74,656 markers. Arrays were hybridized to 57 independent parasite samples (Table S1), including 17 previously sequenced strains used as a validation set. Genotype calls were produced using the BRLMM-P algorithm [40]. Markers that did not demonstrate perfect concordance between sequence and array data for the 17 strains were removed (Text S1). The remaining 17,582 SNPs constituted the high-confidence marker set used throughout this study (median marker spacing 444 bp, mean spacing 1,316 bp). All genomic positions and translation consequences are listed with respect to the PlasmoDB 5.0 assembly and annotation. SNP genotype data are publicly available on plasmodb.org (release 6.0, July 2009) and dbSNP (Build B134, May 2011), accessible by searching for submission batches Pf_0002 (sequencing of nine isolates) and Pf_0003 (genotyping of 57 isolates) from submitter BROAD-GENOMEBIO. Genotype data is also available as Dataset S2.

Principal Component Analyses

Principal components analysis (PCA) was performed using the program SmartPCA [41]. All single-infection samples were used for the analysis in Figure 1. Samples that tightly clustered with the wrong continental population (A4, Malayan Camp and T2_C6) represented likely cases of contamination and were thus omitted from all other analyses.

Diversity/Divergence Analysis

We measured diversity using a statistic we term ‘SNP π,’ which quantifies the average number of pair-wise differences among samples from a given population at assayed
SNPs. Population divergence was measured using $F_{ST}$, calculated using the method of Hudson, et al. [42]. Statistical evaluation of the significance of differences in SNP $\pi$ and $F_{ST}$ among populations was performed using a bootstrapping approach, where the SNP set was re-sampled with replacement and each statistic recomputed 1000 times.

**Linkage Disequilibrium (LD) Analysis**

The statistic $r^2$ was calculated within each population for all pairs of SNPs sharing the same chromosome [43]; pairs were binned by distance and averaged within each bin. The level of LD between unlinked markers was estimated by calculating $r^2$ between all pairs of SNPs on different chromosomes. To determine the bias caused by small sample size, the unlinked calculation was repeated, with the change that for each pair of SNPs, the genotype for one was taken from one strain while the genotype for the second was taken from another strain. This background value of $r^2$ was calculated separately for the possible pairs of different strains and then averaged. Only single infections, as assessed by molecular barcode, were used.

**Long Range Haplotype (LRH) Analysis**

Because of the small number of samples, LRH results for individual continental populations had a high level of variance. Thus, we pooled together samples from Africa ($n = 26$) and Asia ($n = 18$, excluding India), as suggested by our PCA analysis. SNPs included in the analysis had a minor allele frequency of at least 0.05 and a call rate of at least 0.8; missing genotypes were imputed using PHASE. LRH analysis was performed using Sweep. Each SNP defined two core alleles, one base pair in length. We calculated relative extended haplotype homozygosity (REHH) for each core allele, to its left and right [44], yielding up to four REHH scores per SNP locus. We standardized the REHH scores as a function of core allele frequency, defined on a discrete grid from 0.05 to 0.95 with even spaces of 0.025. This yielded a normally-distributed set of $Z$-scores for which we calculated corresponding $P$-values and $Q$-values.

**Genome Wide Association Study (GWAS)**

We performed a GWAS for drug resistance to thirteen antimalarials across 50 of our genotyped samples. 7,437 SNPs that had a minor allele count of five samples as well as an 80% call rate under every phenotype condition were used for GWAS. A Bonferroni significance threshold of $-\log_{10}(P\text{-value}) > 5.17$ was used for all tests. See Text S1 for more details on GWAS methods.

The Efficient Mixed-Model Association (EMMA) test [15] models quantitative trait associations to a data set with complex population structure and hidden relatedness. It calculates a genotype similarity matrix instead of discrete categories and does not require a priori specification of populations. The resulting $P$-value distributions demonstrate little remaining effect from population structure (Figure S8) while retaining power to find a number of associations at genome-wide significance (Figures S8, 2A, Table 1).
The Haplotype Likelihood Ratio (HLR) test [16] models the likelihood that a single, resistant haplotype rose to dominance while all other haplotypes proportionally decreased. PLINK [45] is used to produce sliding window haplotypes across the genome and calculate haplotype frequencies for input to the HLR test. We produced input for all 2-, 4- and 6-marker windows. The LOD scores generated by the HLR test were converted to empirical pointwise \( P \)-values by performing approximately 370,000 permutations of the null model for each test condition, allowing us to calculate empirical \( P \)-values up to a significance of \( 10^{-5.6} \). We preserved population-specific phenotype frequencies by permuting only within each of three populations defined by our PCA analysis (Table S1). Resulting \( P \)-value distributions fit expectations well for the vast majority of test conditions (Figures S9, S10) and the test demonstrates power to detect a number of loci at genome-wide significance (Figure 2A, Table 1).

Copy Number Variation (CNV)

Copy number was assessed by evaluating the hybridization intensity at the \( PF10_0355 \) locus on the high-density SNP array (Text S1). Follow-up analyses were done by quantitative real-time PCR (qPCR) of the \( PF10_0355 \) locus using the Delta Delta Ct method [46]. \( PF10_0355 \) was compared to the reference locus \( PF07_0076 \) and 3D7 was used as a reference strain. A summary of \( PF10_0355 \) copy number for all parasite strains tested is provided in Table S6. Select resistant strains that were found to have multiple copies of \( PF10_0355 \) were further analyzed by quantitative Southern blotting and \( PF10_0355 \) copy number was compared to the \( dhps \) gene from the 3D7 strain [47].

\( \text{PF10}_0355 \) Overexpression

The full length ORF of \( PF10_0355 \) was amplified from either the Dd2 (HFN sensitive) or SenP08.04 (HFN resistant) parasite isolate and cloned into the pBIC009 plasmid under the expression of the \( Hsp86 \) promoter. Plasmid DNA was isolated, transfected into the Dd2 parasite strain and stable transfecants were selected with 2.5nM WR99210 [48]. Parasites from two independent experiments for each vector type (Dd2+Dd2 and Dd2+SenP08.04) were isolated and successful transfection was confirmed by plasmid rescue as well as episome-specific PCR and sequencing. Additionally, a vector control strain was made by transfecting Dd2 parasites with the pBIC009 plasmid containing the firefly luciferase gene (EC 1.13.12.7).

Acknowledgements

References


Table 1. Eleven genome-wide significant associations with antimalarial drug resistance. Positions are given with respect to the PlasmoDB 5.0 reference assembly of 3D7. Drug abbreviations are ATV: atovaquone; CQ: chloroquine; HFN: halofantrine; ADQ: amodiaquine; ARTS: artemisinin. The HLR test for CQ-pfcrt association is just below the genome-wide significance threshold and is omitted here, but is shown in Figure 2C.

<table>
<thead>
<tr>
<th>chr</th>
<th>SNPs</th>
<th>test</th>
<th>drug</th>
<th>P-value</th>
<th>genes</th>
<th>PlasmoDB description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>674,154</td>
<td>EMMA</td>
<td>ATV</td>
<td>2.36E-07</td>
<td>PFF0785w</td>
<td>Ndc80 homologue, putative</td>
</tr>
<tr>
<td>7</td>
<td>459,787</td>
<td>EMMA</td>
<td>CQ</td>
<td>4.72E-07</td>
<td>MAL7P1_27</td>
<td>chloroquine resistance transporter</td>
</tr>
<tr>
<td>10</td>
<td>1,435,226, 1,435,286,</td>
<td>HLR_risk_6</td>
<td>HFN</td>
<td>4.71E-06,</td>
<td>PF10_0355,</td>
<td>erythrocyte membrane protein putative, liver stage antigen 1</td>
</tr>
<tr>
<td></td>
<td>1,435,370, 1,437,695,</td>
<td></td>
<td></td>
<td>4.25E-06</td>
<td>PF10_0356</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,437,718, 1,441,590,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,444,868</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>657,349</td>
<td>EMMA</td>
<td>ATV</td>
<td>4.01E-06</td>
<td>PF11_0178</td>
<td>conserved unknown</td>
</tr>
<tr>
<td>11</td>
<td>738,407</td>
<td>EMMA</td>
<td>HFN</td>
<td>7.20E-07</td>
<td>PF11_0203</td>
<td>peptidase, putative</td>
</tr>
<tr>
<td>11</td>
<td>1,123,028, 1,124,030</td>
<td>HLR_risk_2</td>
<td>ADQ</td>
<td>5.26E-06</td>
<td>PF11_0302</td>
<td>conserved unknown</td>
</tr>
<tr>
<td>12</td>
<td>1,964,935</td>
<td>EMMA</td>
<td>HFN</td>
<td>6.15E-08</td>
<td>PF11_2285c</td>
<td>conserved unknown</td>
</tr>
<tr>
<td>13</td>
<td>757,689</td>
<td>EMMA</td>
<td>HFN</td>
<td>1.28E-07</td>
<td>PF13_0101</td>
<td>conserved unknown</td>
</tr>
<tr>
<td>14</td>
<td>1,233,470</td>
<td>EMMA</td>
<td>HFN</td>
<td>5.32E-07</td>
<td>PF14_0293</td>
<td>conserved unknown</td>
</tr>
<tr>
<td>14</td>
<td>2,814,793, 2,815,714</td>
<td>HLR_risk_2</td>
<td>ARTS</td>
<td>4.90E-06</td>
<td>PF14_0654</td>
<td>aminophospholipid transporter, putative</td>
</tr>
<tr>
<td>14</td>
<td>3,130,449</td>
<td>EMMA</td>
<td>ATV</td>
<td>1.03E-06</td>
<td>PF14_0729</td>
<td>early transcribed membrane protein 14.2</td>
</tr>
</tbody>
</table>
Figure 1. Parasite global population structure and genetic diversity vs. divergence. (A) Population structure is visualized using the first two principal components of genetic variation for 57 parasites. Solid circles represent individual parasites, with colors assigned by reported origin: Africa in red, America in blue, and Asia in green. The nine strains used for ascertainment sequencing are indicated with (*). (B) Genetic diversity (SNP $\pi$) in Senegal versus divergence ($F_{ST}$) between Senegal and Thailand is reported for 688 genes containing $\geq$3 successfully genotyped SNPs. Blue diamonds: enzymes, acyl-CoA synthetases (ACS) or transporters; red diamonds: antigens, vars, rifins, stevors or surfins; gray diamonds: all other genes. Gene IDs (PlasmoDB.org) for highlighted genes are listed in Table S7. A gene with unknown function is flagged with (*) to indicate that SNP $\pi$ is off-scale (0.014).

Figure 2. Genome-wide association study (GWAS) results. (A) Genome-wide significant associations were found for five antimalarials (out of thirteen tested) using EMMA and HLR tests. They include $pfcrt$ (chromosome 7) associated with chloroquine resistance and eleven novel associations with resistance to several drugs, listed in Table 1. (B) Quantile-quantile plots for the $P$-value distributions in (A) show no significant confounding from population structure. Bonferroni-corrected genome-wide significance is marked with a dashed line; Benjamini-Hochberg significance is marked with a dotted line. (C-D) Close-ups are shown of the GWAS signal (top) and haplotypes (bottom) for resistance to (C) chloroquine (CQ) around the gene $pfcrt$ and (D) halofantrine (HFN) around the gene $PF10_0355$. Yellow: sensitive allele; red: resistant allele; Blue: no data. Isolates are ordered by IC$_{50}$, with the highest IC$_{50}$ on the bottom.

Figure 3. Overexpression of $PF10_0355$ decreases parasite susceptibility to halofantrine (HFN) and related antimalarials. Parasite susceptibility to six antimalarials was measured by $^{3}$H-hypoxanthine incorporation. Comparisons were made between Dd2 (HFN-sensitive strain) and SenP08.04 (HFN-resistant strain), as well as 4 transfected lines. “Dd2+Dd2”: Dd2 parasites overexpressing $PF10_0355$ from Dd2; “Dd2+P08”: Dd2 parasites overexpressing $PF10_0355$ from SenP08.04. Overexpression of $PF10_0355$ decreases parasite susceptibility to (A) HFN and structurally related (B) mefloquine (MFQ) and (C) lumefantrine (LUM). Overexpression of $PF10_0355$ does not alter parasite susceptibility to (D) chloroquine (CQ), (E) artemisinin (ARTS) or (F) atovaquone (ATV). Mean IC$_{50}$ ± standard error is shown. Significance levels: *: p<0.05, **: p<0.01, ***: p<0.001.

Figure 4. Correlations between antimalarial drugs tested. (A) Pearson correlation values ($r$) between log$_{10}$(IC$_{50}$) values are rendered as a color in a symmetric correlation matrix (red: correlated; white-uncorrelated, blue: inversely correlated). Thirteen antimalarials are measured: artemether (ARTM), artesunate (ARTN), artemisinin (ARTS), dihydroartemisinin (DHA), halofantrine (HFN), lumefantrine (LUM), mefloquine (MFQ), quinine (QN), chloroquine (CQ), amodiaquine (ADQ), atovaquone (ATV), piperaquine (PIP), and halofuginone (HFG). Drugs are grouped by structural relatedness. (B-F) Correlation plots are given with a linear regression line for HFN compared to the 5 other drugs tested for antimalarial resistance with $PF10_0355$ overexpression: (B) LUM, (C) MFQ, (D) ATV, (E) CQ, and (F) ARTS.
Figure 5. Copy number variation at PF10_0355 is associated with HFN resistance.

(A). Mean PF10_0355 copy number (± standard deviation for three replicates) in the parent Dd2 and transfected lines from qPCR analysis. Dd2+Dd2: Dd2 parasites overexpressing PF10_0355 from HFN-sensitive Dd2; Dd2+P08: Dd2 parasites overexpressing PF10_0355 from HFN-resistant SenP08.04. Copy number was compared to the reference locus PF07_0076. (B) Increased hybridization intensity at PF10_0355 on the high-density SNP array, measured by Z-scores for normalized and background-corrected data, for the HFN-resistant isolate SenP19.04. (C) Strains with increased copy number of PF10_0355 (as measured by qPCR > 1.2x 3D7) show a significantly higher resistance to HFN (p = 0.02, Student t-test).
<table>
<thead>
<tr>
<th></th>
<th>ARTM</th>
<th>ARTN</th>
<th>ARTS</th>
<th>DHA</th>
<th>HFN</th>
<th>LUM</th>
<th>MFQ</th>
<th>QN</th>
<th>CQ</th>
<th>ADQ</th>
<th>ATV</th>
<th>PIP</th>
<th>HFG</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARTM</td>
<td>1</td>
<td>0.8</td>
<td>0.9</td>
<td>0.9</td>
<td>0.2</td>
<td>0.5</td>
<td>0.5</td>
<td>0.6</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0</td>
<td>-0.1</td>
</tr>
<tr>
<td>ARTN</td>
<td>0.8</td>
<td>1</td>
<td>0.8</td>
<td>0.7</td>
<td>0.1</td>
<td>0.3</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
<td>0.3</td>
<td>0.4</td>
<td>0.1</td>
<td>0</td>
</tr>
<tr>
<td>ARTS</td>
<td>0.9</td>
<td>0.8</td>
<td>1</td>
<td>0.8</td>
<td>0.7</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.1</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>DHA</td>
<td>0.9</td>
<td>0.7</td>
<td>0.8</td>
<td>1</td>
<td>0.5</td>
<td>0.6</td>
<td>0.6</td>
<td>0.5</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
<td>0</td>
</tr>
<tr>
<td>HFN</td>
<td>0.2</td>
<td>0.1</td>
<td>0.7</td>
<td>0.5</td>
<td>1</td>
<td>0.7</td>
<td>0.6</td>
<td>0.2</td>
<td>-0.3</td>
<td>0</td>
<td>0.1</td>
<td>-0.2</td>
<td>0</td>
</tr>
<tr>
<td>LUM</td>
<td>0.5</td>
<td>0.3</td>
<td>0.6</td>
<td>0.6</td>
<td>0.7</td>
<td>1</td>
<td>0.8</td>
<td>0.2</td>
<td>-0.3</td>
<td>-0.2</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>MFQ</td>
<td>0.5</td>
<td>0.4</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.8</td>
<td>1</td>
<td>0.3</td>
<td>-0.1</td>
<td>0</td>
<td>0.1</td>
<td>-0.2</td>
<td>0</td>
</tr>
<tr>
<td>QN</td>
<td>0.6</td>
<td>0.5</td>
<td>0.6</td>
<td>0.5</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
<td>1</td>
<td>0.5</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>CQ</td>
<td>0.3</td>
<td>0.3</td>
<td>0.1</td>
<td>0.2</td>
<td>-0.3</td>
<td>-0.3</td>
<td>-0.1</td>
<td>0.5</td>
<td>1</td>
<td>0.5</td>
<td>0.6</td>
<td>0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>ADQ</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0</td>
<td>-0.2</td>
<td>0</td>
<td>0.3</td>
<td>0.5</td>
<td>1</td>
<td>0.2</td>
<td>0.1</td>
<td>-0.3</td>
</tr>
<tr>
<td>ATV</td>
<td>0.2</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.3</td>
<td>0.6</td>
<td>0.2</td>
<td>1</td>
<td>0.3</td>
<td>0</td>
</tr>
<tr>
<td>PIP</td>
<td>0</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.2</td>
<td>0.1</td>
<td>-0.2</td>
<td>0.3</td>
<td>0.5</td>
<td>0.1</td>
<td>0.3</td>
<td>1</td>
<td>0.7</td>
</tr>
<tr>
<td>HFG</td>
<td>-0.1</td>
<td>0</td>
<td>-0.1</td>
<td>0</td>
<td>0</td>
<td>0.2</td>
<td>0</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.3</td>
<td>0</td>
<td>0.7</td>
<td>1</td>
</tr>
</tbody>
</table>

**Graphs**

- **A**: Correlation matrix with colors indicating the strength of correlation.
- **B**: Scatter plot with linear regression line for LUM vs HFN, $r = 0.728$.
- **C**: Scatter plot with linear regression line for MFQ vs HFN, $r = 0.61$.
- **D**: Scatter plot with linear regression line for ATV vs HFN, $r = 0.075$.
- **E**: Scatter plot with linear regression line for CQ vs HFN, $r = -0.296$.
- **F**: Scatter plot with linear regression line for ARTS vs HFN, $r = 0.669$. 

**Correlation Coefficients**

- $r = 0.075$ for ATV vs HFN
- $r = 0.669$ for ARTS vs HFN
- $r = 0.728$ for LUM vs HFN
- $r = 0.61$ for MFQ vs HFN
- $r = -0.296$ for CQ vs HFN